421 related articles for article (PubMed ID: 23378460)
1. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.
Becker MO; Radic M; Schmidt K; Huscher D; Riedlinger A; Michelfelder M; Meisel C; Ewert R; Burmester GR; Riemekasten G
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):274-284. PubMed ID: 32476963
[TBL] [Abstract][Full Text] [Related]
3. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
Wu M; Baron M; Pedroza C; Salazar GA; Ying J; Charles J; Agarwal SK; Hudson M; Pope J; Zhou X; Reveille JD; Fritzler MJ; Mayes MD; Assassi S
Arthritis Rheumatol; 2017 Sep; 69(9):1871-1878. PubMed ID: 28575534
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
5. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
6. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
[TBL] [Abstract][Full Text] [Related]
7. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
8. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
9. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
14. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
15. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
16. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
17. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
18. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
19. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
[TBL] [Abstract][Full Text] [Related]
20. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?
Liu X; Mayes MD; Pedroza C; Draeger HT; Gonzalez EB; Harper BE; Reveille JD; Assassi S
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1375-80. PubMed ID: 23401350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
